Important Message: Beware of Impersonation Scams

Fraudulent messages and advertisements are currently circulating on messaging platforms, including WhatsApp, impersonating Candriam’s brand and investment professionals. Please note that Candriam never offers investment recommendations or provides financial advice through social media channels or messaging platforms.

Latest insights

Middle East Conflict

Asset Allocation, Geopolitics
Coordinated U.S. and Israeli strikes against Iran began on Saturday 28 February, while Iranian retaliation has spread across the region. Without any clearly stated intentions or objectives on the part of the United States of America, these events give rise to numerous hypotheses and uncertainties for the region in the coming months, as well as risks for investors.
  • Equities, AI, Felix Demaeght

    Software: Will AI trigger a SaaSpocalypse?

    Artificial Intelligence agents are moving beyond assistance and into execution. The emergence of AI agents such as Claude Cowork has intensified a debate among investors: could parts of the SaaS ecosystem risk structural disintermediation?
  • Research Paper, Lucia Meloni, Emma Miguel Unzue, ESG, SRI

    Brand Values: Unravelling Luxury Goods Risks

    If brand value is image, reputation, and a track record of quality, the higher the price of the product, the more important that image is for pricing and profit. And the more susceptible to negative news which might affect that image.
9 results found
  • Healthcare
Show me
  • Topic
  • Theme
  • Publication
  • Expert
Show me
  • Topic
  • Theme
  • Publication
from
  • Expert
9 results found
  • Healthcare
Healthcare, ESG, SRI

Why healthcare, why now?

On Tuesday, September 30, the pharmaceutical industry issued its first formal response to President Trump’s recent letter on drug pricing, announcing a deal between Pfizer and the US administration.
ESG, SRI, Oncology, Healthcare

From uncertainty to growth: why invest in healthcare?

As we enter the month of October, investors are faced with an obvious question: is the time right for new investments in the oncology sector? Pasquale Sansone, Senior Biotechnology Analyst, shares his analysis and convictions.
Ken Van Weyenberg, Oncology, ESG, SRI, Healthcare

Why oncology remains a key investment opportunity

The investment landscape is marked by persistent macroeconomic uncertainties, uneven growth, and heightened geopolitical risks. Despite attractive earnings growth, healthcare has also been under pressure due to regulatory restructuring, drug pricing debates, budget constraints, and tariff concerns.
Servaas Michielssens, Equities, Healthcare

Pharma tariffs: a complex puzzle

On Sunday, July 27, 2025, the EU and the US successfully concluded a trade agreement, paving the way for strengthened economic relations between the two regions. While initial reports caused some confusion, it now appears that most pharmaceutical products, excluding certain generics, will be subject to a 15% tariff.
Equities, Healthcare, Servaas Michielssens, Linden Thomson

Biotech : 25 years of innovation in the service of healthcare

Over the past twenty-five years, the medical biotechnology sector has profoundly transformed the therapeutic landscape. From the fight against cancer to the development of Covid-19 vaccines in record time, advances in biopharma have changed the outcome for millions of patients worldwide.
Equities, Healthcare, Servaas Michielssens, Linden Thomson

Time to Re-engage with Healthcare?

Healthcare share prices tend to reflect some trepidation leading up to and shortly after the US presidential elections, yet for the last five elections the sector outperformed in the 12 months following the election.
Q&A, Healthcare, Linden Thomson, Servaas Michielssens

Biotech investing: is there a doctor in the house?

Servaas Michielssens and Linden Thomson answer investors’ questions about a sector where depth of specialist knowledge is a prerequisite to consistent stock selection success.
Load more

Find it fast

Get information faster with a single click

Get insights straight to your inbox